BiomX Inc. (NYSEAMERICAN:PHGE – Free Report) – Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of BiomX in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($1.90) per share for the year, up from their previous estimate of ($2.92). HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for BiomX’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for BiomX’s FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.
BiomX Price Performance
Shares of NYSEAMERICAN:PHGE opened at $0.63 on Thursday. BiomX has a 52-week low of $0.48 and a 52-week high of $4.99. The company has a market capitalization of $11.44 million, a price-to-earnings ratio of -0.20 and a beta of 1.27.
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Stock Market Upgrades: What Are They?
- Tesla Stock: What To Expect With Their Delivery Numbers Report
- 3 Grocery Stocks That Are Proving They Are Still Essential
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- Top Biotech Stocks: Exploring Innovation Opportunities
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
